Yamauchi, Yuki
Nakamura, Akinobu
Yokota, Takashi
Takahashi, Kiyohiko
Kawata, Shinichiro
Tsuchida, Kazuhisa
Omori, Kazuno
Nomoto, Hiroshi
Kameda, Hiraku
Cho, Kyu Yong
Anzai, Toshihisa
Tanaka, Shinya
Terauchi, Yasuo
Miyoshi, Hideaki
Atsumi, Tatsuya
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology (19K08992)
Japan Association for Diabetes Education and Care
Akiyama Life Science Foundation
Takeda Science Foundation
Suhara Memorial Foundation
Japan Science and Technology Agency (JPMJCE1301)
Article History
Received: 17 November 2021
Accepted: 30 May 2022
First Online: 13 June 2022
Competing interests
: A.N. obtained research funding by Taisho Pharmaceutical co., Ltd., the manufacturer of luseogliflozin. The funder had no role in study design, data collection and analysis, decision to publish or preparation of manuscript. The other authors do not have any competing interests.